UPDATED: Congressional reps urge the NIH to ‘march in’ on rising drug prices

Emily Wasserman Up in arms about rising drug prices, a cadre of lawmakers have called for Congressional action. But the lawmaking process won't happen quickly enough for some of ...

GlaxoSmithKline and Five Prime ditch lung cancer ambitions as rivals pile in

Damian Garde Partners GlaxoSmithKline and Five Prime Therapeutics are abandoning their hopes of developing an early-stage drug for lung cancer, pivoting to mesothelioma as the landscape ...

Interim Valeant CEO Schiller expects to stick to the script–and that means being ‘boring’ in 2016

Carly Helfand When Valeant installed former CFO Howard Schiller as interim CEO earlier this week, it said the board would continue to work closely with Schiller to implement company ...

Boehringer Ingelheim will hire 400, invest €500M in Vienna biologics operation

Eric Palmer Germany's Boehringer Ingelheim has been swapping out operations and changing up top management as it scrambles to recover from patent losses that have flattened its ...

Adamas soars as its Parkinson’s drug comes through in Phase III

Damian Garde Adamas Pharmaceuticals' lead drug met its main goals of reducing side effects related to Parkinson's disease treatment in a late-stage trial, the company said, ...

What’s the calendar bringing biopharma next year? Our top 5 ideas

Tracy Staton Winter days are short and dark. December is winding down. If you're not already on a holiday break, you likely will be soon. So, it's a good time to take a minute ...

Shkreli charges prompt Nasdaq to delist KaloBios

Carly Helfand Martin Shkreli has already been ousted as CEO of KaloBios. And now, Nasdaq plans to delist the company, citing Shkreli's recent arrest on fraud and looting charges ...

Zoetis hives off 3 manufacturing plants in deal with Bulgarian drugmaker

Tracy Staton Zoetis, under pressure from investors to shape up, laid out a sweeping plan earlier this year to eliminate 10 plants and about 2,500 jobs as part of an effort ...

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

John Carroll The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015. FierceBiotech News

Sorry, pharma. Martin Shkreli’s disgrace won’t take the heat off your pricing

Tracy Staton Pharma might think that bad boy Martin Shkreli's arrest will give the rest of the industry a breather. Though Turing Pharmaceuticals' now-ex-CEO triggered a public ...

After a 7-year odyssey at the FDA, Merck finally wins an OK for Bridion

John Carroll For the past 7 years Merck has maintained a star rating by its program for Bridion (sugammadex), remaining convinced of its big market potential and staying upbeat after ...

What can Gilead, Biogen and Celgene teach Big Pharma about R&D?

John Carroll For the past 5 years the biopharma experts at Deloitte have been keeping an eye on a disturbing trend that shows no sign of letting up anytime soon. The biggest players ...
Page 2 of 9812345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS